EBV EA IgG Kit ELISA

N° du produit ABIN996987

Ce kit ELISA Epstein-Barr Virus (EBV) EBV EA IgG est un kit ELISA Colorimetric conçu pour quantifier Epstein-Barr Virus (EBV) EBV EA IgG.

Aperçu rapide pour EBV EA IgG Kit ELISA (ABIN996987)

Antigène: EBV EA IgG (Anti-Epstein-Barr Virus Early Antigen IgG (EBV EA IgG))

Reactivité: Epstein-Barr Virus (EBV)

Méthode de détection: Colorimetric

Application: ELISA

Type d'échantillon: Serum

Détail du produit EBV EA IgG Kit ELISA

Analytical Method: Qualitative

Specificité: 100%

Sensibilité: 100%

Information d'application

Volume d'échantillon: 5 μL

Durée du test: 1 - 2 h

Plaque: Pre-coated

Restrictions: For Research Use only

Stockage

Stock: 4 °C

Date de péremption: 12-18 months

Détail du antigène

Antigène: EBV EA IgG (Anti-Epstein-Barr Virus Early Antigen IgG (EBV EA IgG))

Autre désignation: Epstein Barr Virus Early Antigen (EA) IgG

Classe de substances: Antibody, Antibody

Sujet: Detection of the Epstein-Barr virus was first described in 1964 by Epstein, Achong, and Barr using electron microscopic studies of cultured lymphoblasts derived from patients with Burkitt’s lymphoma. EBV is classified as a member of the herpes-virus family based upon it’s characteristic morphology. EBV infection may demonstrate a wide spectrum of clinical symptoms. The majority of primary EBV infections are transmitted via saliva, occur during childhood, and are subclinical. In the U.S., 50% of the population demonstrate EBV antibodies before the age of 5 years, 80% by adulthood. Transfusion-associated EBV infections have also been reported. In young adults, EBV infection may be clinically manifested as Infectious Mononucleosis (IM) with typical symptoms of sore throat, fever, and lymphadenopathy. College students and military personnel are often cited as a high morbidity incidence population for IM3. Following primary EBV infection, it is postulated that the B lymphocyte may continue to harbor the EBV genome and establish a latent infection that may extend through life. Reactivation of EBV infection or enhanced EBV activation has been documented in immunodeficient or immunosuppressed patients, i.e., organ transplant patients, individuals with malignancies, pregnant women, and persons of advanced age.

Epstein-Barr virus has also been associated in the pathogenesis of two human cancers, Burkitt’s lymphoma and nasopharyngeal carcinoma (NCP). Documentation by means of DNA hybridization studies demonstrates the presence of the EBV genome on biopsy specimens taken from individuals with these carcinomas. Burkitt’s lymphoma is primarily observed in Sub-Sahara Africa, especially in African children, and in New Guinea. Malarial infections are usually diagnosed in Burkitt’s lymphoma patients and are suggested to be a co-factor. Nasopharyngeal carcinoma is observed in Asia, most notably in Southern China, and may have genetic or environmental influences as the co-factor5,6. Serological studies have shown that the clinical onset of NPC is preceded by the appearance of a high antibody titer of IgA to viral capsid antigens and early antigens. The titers increase with the total tumor burden and the antibodies decline with the response to therapy. In patients with confirmed clinical remission elevation of IgA serological titers is highly significant for prediction of relapse.